Brokerage firms Nuvama, CLSA, and Macquarie have highlighted strong growth prospects for TCS, Bajaj Finance, and IRCTC, ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Of this, the startup has already pocketed $10 Mn from Nuvama Private Wealth and a US-based VC firm will infuse another $10 Mn ...

DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

TCS shares surge 6% post Q3 results, brokerages optimistic, net profit up 5.5%, dividend declared, target prices revised.

Avenue Supermarts, operator of DMart, is expected to report an 18% YoY revenue growth to Rs 16,016 crore for Q3FY25, with net ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

Multi-Manager ICVC also sold 4.35 lakh shares or 0.52 percent stake in Dr Lal PathLabs at Rs 2,997.11 per share.